Publications scientifiques en 2025

Depuis le 05/01/2026
  1. Safety profile of trastuzumab originator vs biosimilars: a systematic review and meta-analysis of randomized clinical trials.
    Oliva A, Scavone C, Riccardi C, Bernardi FF, Salvo F, Mascolo A.
    Clin Transl Oncol. 2025
  2. Association of fluoroquinolones with the risk of spontaneous pneumothorax: nationwide case-time-control study.
    Bénard-Laribière A, Pambrun E, Kouzan S, Faillie JL, Bezin J, Pariente A.
    Thorax. 2025
  3. Clozapine and objective assessment of hypersomnolence in patients with schizophrenia: a systematic review.
    Quiles C, Taillard J, Lopez R, Geoffroy PA, Salvo F, Micoulaud-Franchi JA.
    J Sleep Res. 2025
  4. Inputs of pharmacoepidemiology in addictovigilance: How do they fit together?
    Soeiro T, Daveluy A, Victorri-Vigneau C, Lapeyre-Mestre M, Micallef J.
    Therapie. 2025
  5. From regional signal to alert in addictovigilance.
    Daveluy A, Perino J, Gibaja V, Le Boisselier R, Batisse A, Miremont-Salamé G, Peyré A, Boucher A, Frauger E, Micallef J, Peyrière H.
    Therapie. 2025
  6. ASOS, a national monitoring study to assess narcotic prescriptions and indications in France since 2001.
    Perri-Plandé J, Miremont-Salamé G, Lapeyre-Mestre M, Perino J, Gibaja V, Daveluy A; French Addictovigilance Network.
    Therapie. 2025
  7. The enhanced national pharmacovigilance system implemented for COVID-19 vaccines in France: A 2-year experience report.
    Crommelynck S, Grandvuillemin A, Ferard C, Mounier C, Gault N, Pierron E, Jacquot B, Vaillant T, Chatelet IPD, Jacquet A, Salvo F, Alt M, Bagheri H, Micallef J, Pariente A, Gautier S, Valnet-Rabier MB, Atzenhoffer M, Lepelley M, Cottin J, Lacroix I, Gras V, Massy N, Dhanani A, Vella P, Shaim Y, Baril L, Jonville-Béra AP, Benkebil M; 30 French Regional Pharmacovigilance Centres.
    Therapie. 2025
  8. Early Detection of Hearing Impairment Signals Post-mRNA COVID-19 Vaccination: A Disproportionality Analysis Study on French Pharmacovigilance Database.
    Boulefaa D, Bagheri H, Salvo F, Rabier MB, Geniaux H, Lepelley M, Rocher F, Mahe J, Grandvillemuin A, Thai-Van H.
    Drug Saf. 2025
  9. Shaping the future of pharmacoepidemiology in France: Recommendations from the SFPT Pharmacoepidemiology Working Group.
    Soeiro T, Allouchery M, Bene J, Bezin J, Dolladille C, Faillie JL, Grimaldi L, Kaguelidou F, Khouri C, Lafaurie M, Largeau B, Montastruc F, Morin L, Scailteux LM, Pariente A; SFPT Pharmacoepidemiology Working Group.
    Therapie. 2025
  10. Ethics and clinical research: How can the Ethics Committees (CPPs) and Committees for Research Ethics (CER) evolve?
    Berdaï D, Guérin A, Pérol D, Girault C, Molimard M, Amiel P, Beaussier H, Bertoye PH, Cornu C, Deplanque D, Dreyfuss D, Duchossoy L, Fouret C, Haaser T, Le Louarn A, Rifai S, Thierry JP.
    Therapie. 2025
  11. Successful Linkage of Electronic Medical Records and National Health Data System in Type 2 Diabetes Research: Methodological Insights and Implications.
    Goff RL, Brice S, Contini A, Boussac M, Souche A, Belloc F, Coulombel N, Collin C, Gouverneur A, Molimard M.
    Pharmacoepidemiol Drug Saf. 2025
  12. Impact of psychedelics on craving in addiction: A systematic review.
    Chapron SA, Bonazzi G, Di Lodovico L, de Ternay J, Landmann C, Nourredine M, Salvo F, Sessa B, Das R, Rolland B, Garcia-Romeu A, Auriacombe M.
    J Psychopharmacol. 2025
  13. Psychoactive cocktail consumption on Reunion Island: A case report.
    Guyon J, Maillot A, Bastard S, Weisse F, Daveluy A, Mété D.
    J Anal Toxicol. 2025
  14. Are Causal Statements Reported in Pharmacovigilance Disproportionality Analyses Using Individual Case Safety Reports Exaggerated in Related Citations? A Meta-epidemiological Study.
    Bernardeau C, Revol B, Salvo F, Fusaroli M, Raschi E, Cracowski JL, Roustit M, Khouri C.
    Drug Saf. 2025
  15. Guidelines and Best Practices for the Use of Targeted Maximum Likelihood and Machine Learning When Estimating Causal Effects of Exposures on Time-To-Event Outcomes.
    Talbot D, Diop A, Mésidor M, Chiu Y, Sirois C, Spieker AJ, Pariente A, Noize P, Simard M, Luque Fernandez MA, Schomaker M, Fujita K, Gnjidic D, Schnitzer ME.
    Stat Med. 2025
  16. Second primary cancers and hormonal therapies for prostate cancer: A nested case-control study.
    Scailteux LM, Bezin J, Gundelwein M, Edeline J, Oger E, Balusson F, Pariente A.
    Fundam Clin Pharmacol. 2025
  17. Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demorgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  18. Changes in the Ambulatory Use of Antibiotics in France Due to the COVID-19 Pandemic in 2020-2022: A Nationwide Time-Series Analysis.
    Rousselot N, Brayan T, Dumartin C, Clément M, Pariente A.
    Ann Fam Med. 2025
  19. Gloves Standards and Occupational Exposure to Antineoplastic Drugs in the European Context.
    Swierczynski G, Canal-Raffin M, Tuduri L.
    Health Sci Rep. 2025
  20. The latest updates on the proper use of fluoroquinolones - Actualisation 2025 update by the SPILF and the GPIP.
    Vuotto F, Bru JP, Canaoui E, Caseris M, Chopin MCC, Cohen R, Diamantis S, Dihn A, Fillatre P, Gauzit R, Gillet Y, Jonville-Bera AP, Lafaurie M, Lesprit P, Lorrot M, Lourtet J, Maulin L, Poitrenaud D, Pariente A, Raymond J, Strady C, Stahl JP, Varon E, Welker Y, Bonnet E.
    Infect Dis Now. 2025
  21. Interplay of Spontaneous Reporting and Longitudinal Healthcare Databases for Signal Management: Position Statement from the Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Crisafulli S, Bate A, Brown JS, Candore G, Chandler RE, Hammad TA, Lane S, Maro JC, Norén GN, Pariente A, Russom M, Salas M, Segec A, Shakir S, Spini A, Toh S, Tuccori M, van Puijenbroek E, Trifirò G; Real-World Evidence and Big Data Special Interest Group of the International Society of Pharmacovigilance.
    Drug Saf. 2025
  22. The safety profile of fluoroquinolones.
    Jonville-Béra AP, Largeau B, di Meglio F, Pariente A.
    Infect Dis Now. 2025
  23. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  24. Effectiveness of Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure Patients: A Nationwide Population-Based Cohort Study.
    Gautier P, Elbaz M, Bezin J, Delmas C, Cherbi M, Bouisset F, Vindis C, Renoux A, Lafaurie M, Montastruc F.
    JACC Heart Fail. 2025
  25. Effect of the COVID-19 epidemic on the association between antihypertensive drug interruption and the risk of major cardiovascular event in France.
    Mathieu C, Bezin J, Pariente A.
    Am J Hypertens. 2025
  26. Medication errors in malaria management in children: insights from pharmacovigilance data in the Democratic Republic of Congo.
    Amba MN, Ntambwe EK, Biongo AE, Ntamabyaliro N, Kahunu GM, Mabiala JB, Ndosimao CN, Lutete GT, Miremont-Salamé G, Fourrier-Réglat A.
    BMC Pharmacol Toxicol. 2025
  27. Contribution of Addictovigilance data to assess adverse-events linked to psychoactive substances in children and adolescents.
    Peyrière H, Batisse A, Sam-Laï NF, Daveluy A, Fournier-Choma C, Deheul S, Chevalier C, Lacroix C, Gibaja V, Aquizerate A, Pain S, Jouanjus E, Picot MC, Nogue E.
    Br J Clin Pharmacol. 2025
  28. Letter to the Editor from Raschi et al.: "Endocrine adverse reactions of tyrosine kinase inhibitors in combination with immune checkpoint inhibitors".
    Raschi E, Donati M, Salvo F, Khouri C.
    J Clin Endocrinol Metab. 2025
  29. Correction: Major Adverse Cardiovascular Events Related to JAK Inhibitors: A Disproportionality Analysis Using the WHO Global Individual Case Safety Database.
    Di Napoli R, Richez C, Scavone C, Singier A, Demourgues M, Mascolo A, Capuano A, Salvo F.
    Drug Saf. 2025
  30. Use and Potential Misuse of GLP-1 Receptor Agonists in France: a Nationwide Cohort Study.
    du Soulier N, Pariente A, Bezin J, Grenet G, Faillie JL, de Germay S.
    Value Health. 2025
  31. Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study.
    Laurent E, Godillon L, Tassi MF, Marcollet P, Chassaing S, Decomis M, Bezin J, Laure C, Angoulvant D, Range G, Grammatico-Guillon L.
    Front Cardiovasc Med. 2025
  32. Characteristics of Drug-RElated Hospitalizations for Nursing HOme Residents: Cross-Sectional RENHO Study.
    Lopez A, Alfarano C, Lepetit M, Chebane L, Redjimi N, Couret A, Fabre D, Gardette V, Berdaï D, Lapeyre-Mestre M, Bagheri H.
    Drug Saf. 2025
  33. Experimental protocols and models for assessing the permeation of antineoplastic drugs through gloves: From a scoping review to a guidelines proposition for future studies.
    Swierczynski G, Guyon J, Molimard M, Garrigou A, Baldi I, Verdun-Esquer C, Villa A, Canal-Raffin M.
    J Hazard Mater. 2025
  34. Oncologists' knowledge, practices and ethical opinions about therapeutic misconception: a French national survey.
    Haaser T, Clair S, Marty S, Berdai D, Hoarau H, Saux MC, Dreyfuss D, Maternowski PJ.
    BMC Med Ethics. 2025
  35. Development and Validation of a LC-MS/MS Method for Ripretinib and Its Metabolite: Example of a Journey From Laboratory Bench to Routine Application With a Greenness Assessment.
    Rakotovao C, Sharanek A, Burban A, Gueroue P, Bouchet S, Bouguéon G, Ducint D, Molimard M, Italiano A, Djabarouti S, Guyon J.
    Biomed Chromatogr. 2025
  36. Therapeutic Drug Monitoring of Long-Acting Cabotegravir and Rilpivirine in a National Cohort of People With Human Immunodeficiency Virus Type 1: First Results From the ANRS-MIE CARLAPOP Study.
    Néant N, Lê MP, Bouchet S, Lagoutte-Renosi J, Grégoire M, Parant F, Venisse N, Lalanne S, Lemaitre F, Muret P, Renou Q, Destere A, Gandia P, Flandre P, Peytavin G, Solas C; ANRS-MIE-CARLAPOP Study Group.
    Clin Infect Dis. 2025
  37. FDA Adverse Event Reporting System Essentials: A Reflection on Study Conception.
    Raschi E, Cutroneo P, Salvo F, Tuccori M, Khouri C.
    Clin Pharmacol Ther. 2025
  38. Effectiveness and safety of rivaroxaban vs. apixaban in patients with atrial fibrillation and peripheral artery disease.
    Dari L, Beradid S, Constans J, Pariente A, Renoux C.
    Eur Heart J Cardiovasc Pharmacother. 2025
  39. Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2.
    Lafay-Chebassier C, Girodet PO, Laine F, Allain JS, Pickering G, Latreille M, Demina A, Chevassus H, Ingrand I, Tartour E, Benhamouda N, Fraisse ML, Chamitava L, Plétan Y, Balland J, Donazzolo Y, Lafont B.
    Nicotine Tob Res. 2025
  40. Correction: Impact of cardiac rehabilitation and treatment compliance after ST-segment elevation myocardial infarction (STEMI) in France, the STOP SCA+ study.
    Laurent E, Godillon L, Tassi MF, Marcollet P, Chassaing S, Decomis M, Bezin J, Laure C, Angoulvant D, Range G, Grammatico-Guillon L.
    Front Cardiovasc Med. 2025
  41. Pharmacoepidemiology as the delicate science of constructing robust plausibility where there is no certainty: the case for hypertension in young adults.
    Pariente A.
    Eur Heart J. 2025
  42. How synthetic cannabinoid user profiles and consumption patterns can affect wastewater-based epidemiology.
    Devault DA, Peyré A, Cottereau V, Pleignet E, Daveluy A.
    Environ Sci Pollut Res Int. 2025
  43. Sex Differences in the Use and Discontinuation of Recommended Drugs in Secondary Ischemic Stroke Prevention: A Regional Registry-Based Analysis.
    Perrier J, Domecq S, Lesaine E, Gilbert F, Saillour-Glenisson F, Rouanet F, Bezin J.
    J Womens Health (Larchmt). 2025
  44. Moving towards COPD control: Lessons, challenges, and the role of CONDOR, a new French respiratory research network.
    Ribeiro-Baptista B, Girodet PO, Le Rouzic O, Zysman M, Roche N, Regard L.
    Respir Med Res. 2025
  45. Angiogenesis Inhibitors and Arterial Dissection or Aneurysm in Patients With Metastatic Colorectal Cancer.
    Singier A, Jarne Munoz A, Maumus-Robert S, Bérard X, Pariente A, Bezin J, Kempf E, Noize P.
    JAMA Netw Open. 2025
  46. Impact of Liquid Sublingual Immunotherapy on Health Care Resource Use in Allergic Rhinitis and Asthma in the Real-world EfficAPSI Study.
    Devillier P, Demoly P, Bergmann JF, Delaisi B, Gouverneur A, Vadel J, Collin C, Girard L, Scurati S, Molimard M.
    J Investig Allergol Clin Immunol. 2025
  47. Effectiveness of antihypertensive drugs for secondary prevention of ischaemic stroke: a nationwide historic cohort study.
    Perrier J, Gabet A, Olié V, Pariente A, Tzourio C, Bezin J.
    BMJ Open. 2025
  48. Clinical and toxicological epidemiology of intoxications by new psychoactive substances in Reunion Island.
    Maillot A, Guyon J, Ma-Tsi-Leong M, Berly L, Weisse F, Mahé A, Roux GL, Nativel F, Daveluy A, Puech B, Marteau A, Leroy M, Plé O, Maillard O, Bastard S, Mete D.
    Int J Emerg Med. 2025
  49. The Rising Misuse of Pharmacovigilance Reporting Systems: A Threat to Evidence-Based Medicine.
    Khouri C, Hlavaty A, Fusaroli M, Joshi N, Salvo F, Bate A, Pariente A, Raschi E.
    Clin Pharmacol Ther. 2025
  50. Impact of Regulatory Events on JAK Inhibitor Prescribing in Rheumatoid Arthritis: Insights from the French MAJIK Registry.
    Truchetet ME, Prati C, Thevenot P, Bologna C, Alegria GC, Daien CI, Cornec D, Dernis E, Fautrel B, Pariente A, Roux C, Salmon JH, Sellam J, Hucteau E, Bezin J, Avouac J.
    Joint Bone Spine. 2025
  51. How to differentiate between clinical added value (CAV) V drugs: What are the implications, and what is the access pathway?
    Body C, Chassagnol F, Berdaï D, Bergmann JF, Borget I, Doré C, Durr A, Falissard B, Hudry J, Kowalski B, Maugendre P, Schlumberger N, Wilmet E, Le Jeunne C.
    Therapie. 2025